intrasense sas (ALINS:EN Paris)
intrasense sas (ALINS) Snapshot
|
Open
€5.79
|
Previous Close
€5.79
|
|
|
Day High
€5.79
|
Day Low
€5.68
|
|
|
52 Week High
08/28/12 - €7.65
|
52 Week Low
01/14/13 - €4.90
|
|
|
Market Cap
17.7M
|
Average Volume 10 Days
1.4K
|
|
|
EPS TTM
--
|
Shares Outstanding
3.1M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
intrasense sas (ALINS) Related Businessweek News
No Related Businessweek News Foundintrasense sas (ALINS) Details
Intrasense SAS develops and markets Myrian, a multimodality software platform for the review and analysis of medical images in 3D and 4D to improve diagnostic accuracy, enhance patient management, monitor pathologies, and asses imaging endpoints for clinical trials. It offers Myrian Pro for reading patient CDs, MPR reconstruction, slice thickening, side-by-side comparison, image scrapbook, import, export, print-out, RD burning; and Myrian Advance, a diagnostic workstation in the inmrpretation room, at medical staff meetings, as an add-on to server at the practice, as an extension to PACS, and carried around on laptop. The company also provides Myrian Expert for highlighting specific pathologies; setting lesions in their specific anatomical context; and facilitating communication with clinicians, specialists, and patients. In addition, Intrasense SAS offers for routine diagnosis, surgical planning, oncology, and research; expert, excellence, and external modules; and oncology follow-ups, specialized platforms, clinical trials, OEM solutions, and certifications and DICOM. Further, the company provides guarantee, maintenance, installation, integration, and training services. It sells its products through a distribution network in France, Brazil, the Russian Federation, India, and China; and through agents in Sao Paolo, Berlin, Kuala Lumpur, and Tokyo. Intrasense SAS was founded in 2004 and is headquartered in Montpellier, France.
intrasense sas (ALINS) Key Developments
Intrasense SAS announced that it would fit its platform in 15 hospitals in the USA as part of a clinical trial conducted by a new client. Intrasense has sold its Myrian(R) XP-Lung module, which excels at detecting respiratory pathologies, to a manufacturer of medical devices based in the United States, which is currently conducting a clinical trial subject to approval by the FDA. Myrian(R) XP-Lung was selected pursuant to an invitation to tender to standardize the assessment of the criteria for inclusion of patients at the 15 investigating centers that are taking part in this clinical trial.
Intrasense SAS Presents at Gilbert Dupont 10th Health Midcaps Forum, Jun-12-2012 . Venue: Monceau Rio - Park Monceau, Paris, France.

| Recently Viewed | |||
| ALINS:FP | €5.68 EUR | -0.11 | |
| Company | Last | Change | |
| No competitor information is available for ALINS. | |||
| View Industry Companies | |||
Industry Analysis
ALINS
Industry Average
| Valuation | ALINS | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 5.0x |
|
| Price/Book | 3.5x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 4.3x |
|
Post a JobJobs
- Chicago, IL | DunnhumbyusaPosted: Jun 18
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
Sponsored Financial Commentaries
Sponsored Links
To contact INTRASENSE SAS, please visit www.intrasense.fr. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








